Finally, our findings have clinical significance because they support a model of therapy-related haematological malignancy in which genotoxic cancer therapies kill bone marrow cells in a p53-dependent manner so that rare tumour-initiating cells that already harbour an adaptive mutation preferentially expand as a consequence of treatment46. This evidence concerns the gene TP53 and cancer.